• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Neuropore Therapies appoints Dr. Errol De Souza president and CEO

Neuropore Therapies appoints Dr. Errol De Souza president and CEO

January 23, 2017
CenterWatch Staff

Neuropore Therapies, a biopharmaceutical company discovering and developing novel therapeutics for Parkinson’s disease, Alzheimer’s disease and other neurodegenerative disorders, announced that Errol De Souza, Ph.D. has been appointed president and chief executive officer effective immediately.

“Errol is a proven leader in the biopharmaceutical industry. He possesses the experience, business vision and track record that will take Neuropore to the next phase of its growth as we look to advance compounds from our research pipeline into development,” stated Herbert Moessler, chairman of the board of directors at Neuropore.

"I am delighted to have the opportunity to lead Neuropore at this point in the company's transformation," said Dr. De Souza. "With a strong research platform in the exciting areas of autophagy and neuroinflammation and an established collaboration with a major pharmaceutical company with a compound in clinical development, I believe Neuropore has the potential to deliver significant value for patients and shareholders. I look forward to working with Neuropore's executive team and Board to advance the company."

Previous to Errol De Souza’s appointment at Neuropore, he served as president and chief executive officer of several public (Biodel; Synaptic Pharmaceutical) and private (Archemix) biotech companies.

Dr. De Souza has raised hundreds of million dollars in capital in private (venture) and public sectors. Also, he has been involved in taking companies public (Neurocrine Biosciences IPO), executed M&A deals including Synaptic Pharmaceuticals sale to H. Lundbeck, and has served in a number of high-ranking R&D roles, including senior vice president and U.S. head of R&D for Aventis (now Sanofi; 1998-2002), co-founder and executive vice president of Research and Development at Neurocrine Biosciences (1992-1998), and head of CNS Diseases Research at DuPont Merck (1990 – 1992).

He has extensive board experience and serves or has served on the board of directors of several private companies and public companies.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing